Top Drug-Industry Lobbyist to Step Down After 2020 Election
(Bloomberg) -- Former U.S. Congressman James Greenwood plans to step down as chief executive officer of the Biotechnology Innovation Organization following next year's elections.
Greenwood, 68, will leave the trade and lobbying organization at the beginning of 2021 after serving in its top post for 15 years. BIO, as the group is known, represents some 1,000 biopharmaceutical companies ranging from pharmaceutical bellwethers like Pfizer Inc. to smaller drugmakers such as Intercept Pharmaceuticals Inc.
Greenwood plans to remain in his post through what is expected to be a contentious election cycle where health care and drug pricing will be central issues. He will assist in the search for his successor, said Rich Masters, BIO's executive vice president for public affairs.
“This is a critical moment for our industry as our companies take a beating in the court of public opinion,” said Greenwood in a statement Tuesday. “I will continue my full-throated advocacy to ensure our elected officials do not kill innovation in a populist furor and prevent our scientists from delivering a new generation of genomic cures.”
Greenwood is leading a charge in Washington to limit Medicare recipients' out-of-pocket drug costs. BIO had spent more than $6 million on lobbying this year, according to a September tally from the Center for Responsive Politics. The health-care sector has allocated more funds to lobbying efforts this year than any other industry.
The ground on which the industry's lobbyists are fighting on “has changed substantially with Trump's election,” said Ian Spatz, a senior adviser to Manatt Health, where he consults with pharmaceutical companies, pharmacy-benefit managers and health plans.
News of Greenwood's planned departure was reported earlier Tuesday by Politico.
Prior to joining BIO, Greenwood served as a Republican Congressman in Pennsylvania's eighth district from 1993 to 2005, during which he was a senior member of the Energy and Commerce Committee. He was also a member of a group of GOP moderates known as the Tuesday Group.
Greenwood succeeded BIO's founding president Carl Feldbaum in 2005. As BIO's second-ever leader, the former Congressman oversaw the organization's expansion. The group now has 176 employees and an $85 million operating budget.
To contact the reporter on this story: Riley Griffin in New York at rgriffin42@bloomberg.net
To contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Timothy Annett
©2019 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.